#161782

OV-3133(R) cell line

Cat. #161782

OV-3133(R) cell line

Cat. #: 161782

Organism: Human

Tissue: Derived from ascites of patient diagnosed with high-grade serous ovarian cancer at specific time points at diagnosis and relapse

£575.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Anne-Marie Mes-Masson and Diane Provencher

Institute: Centre Hospitalier de L’université de Montréal

Primary Citation: Létourneau et al. 2012. BMC Cancer. (12): 379. PMID: 22931248

Tool Details
Handling
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: OV-3133(R) cell line
  • Alternate name: OV-3133(R)
  • Organism: Human
  • Gender: Female
  • Tissue: Derived from ascites of patient diagnosed with high-grade serous ovarian cancer at specific time points at diagnosis and relapse
  • Donor: Grade 3 – Stage IIIC; Mutations: TP53 Exon 6; Carboplatin/Taxol
  • Morphology: Formed tumors at subcutaneous sites in SCID mice. No expressionof the tumor suppressor p53 detected. Strong HER2 expression detected in protein extracts and observed in solid tissues by IHC. Spheroid formation: no
  • Growth properties: Adherent
  • Crispr: No
  • Receptors of note: No
  • Description: Epithelial ovarian cancer cell lines spontaneously derived from ascites of patient diagnosed with high-grade serous ovarian cancer at specific time points at diagnosis and relapse (R). Primary treatment included paclitaxel and carboplatin and later treatment included doxorubicin, carboplatin, gemcitabine, and etoposide.
  • Production details: Established from the cellular fraction of ascites collected by centrifugation. The cell lines were then maintained for 40 days in OSE with medium replaced weekly.
  • Additional notes: Patient 3133 received treatment of paclitaxel and carboplatin 1-3 months after sugery and confirmation of ovarian cancer diagnosis. A second sugery 6 months after the first detectede infiltration of the tumor in part of the abdomen. Patient was treated with dxorubicin and later carboplatin and gemcitabine after no significant changes of CA-125 levels were seen. Later imaging presented an increase in tumor mass whereby she was given etoposide orally for eight days.

Handling

  • Growth medium: OSE medium contains 10% FBS, 0.5ug/mL amphotericin B and 50 ug/mL gentamicin
  • Atmosphere: Hypoxic condition of 5%O2 and 5%CO2
  • Cultured in antibiotics: Amphotericin B and Gentamicin

References

  • Tomas et al. 2023. J Ovarian Res. 11
  • 16(1):70. PMID: 37038202 Vias et al. 2023. Elife. 11
  • 12:e83867. PMID: 37166279 Jubelin et al. 2022. Cell Biosci. 11
  • 12(1):155. PMID: 36089610 Canals et al. 2022. Front Oncol. 4
  • 12:856424. PMID: 35600398